Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...
Shares of AbbVie Inc. ABBV slid 1.47% to $171.35 Wednesday, on what proved to be an all-around positive trading session for ...
The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of AbbVie's market standing. Stay informed and make data-driven ...
AbbVie (ABBV) and Regenxbio (RGNX) announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age-Related Macular ...
AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st. Supported by world-class markets data from Dow Jones and FactSet, and partnering with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback